About Diphosphomevalonate decarboxylase
Diphosphomevalonate decarboxylase (MVD) is a protein
from Homo sapiens identified by UniProt accession
P53602, 400 residues long.
MolForge cross-references it against 0 known binders and
79 disease associations.
Target properties
| Protein name | Diphosphomevalonate decarboxylase |
| UniProt accession | P53602 |
| Gene | MVD |
| Organism | Homo sapiens |
| Length | 400 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (79)
Diseases linked to this target (Open Targets).
- disseminated superficial actinic porokeratosis · score 0.66
- neurodegenerative disease · score 0.55
- linear porokeratosis · score 0.32
- lysosomal storage disease · score 0.27
- mean corpuscular hemoglobin · score 0.16
- mean corpuscular volume · score 0.15
- genetic disorder · score 0.12
- airway imaging measurement · score 0.11
- Griscelli syndrome type 3 · score 0.06
- Griscelli disease · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P53602-F1 | alphafold | PREDICTED | 92.15 | — |
Amino-acid sequence (400 residues)
MASEKPLAAV TCTAPVNIAV IKYWGKRDEE LVLPINSSLS VTLHQDQLKT TTTAVISKDF TEDRIWLNGR EEDVGQPRLQ ACLREIRCLA RKRRNSRDGD PLPSSLSCKV HVASVNNFPT AAGLASSAAG YACLAYTLAR VYGVESDLSE VARRGSGSAC RSLYGGFVEW QMGEQADGKD SIARQVAPES HWPELRVLIL VVSAEKKLTG STVGMRASVE TSPLLRFRAE SVVPARMAEM ARCIRERDFP SFAQLTMKDS NQFHATCLDT FPPISYLNAI SWRIIHLVHR FNAHHGDTKV AYTFDAGPNA VIFTLDDTVA EFVAAVWHGF PPGSNGDTFL KGLQVRPAPL SAELQAALAM EPTPGGVKYI IVTQVGPGPQ ILDDPCAHLL GPDGLPKPAA
Explore Diphosphomevalonate decarboxylase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets